Mikhail Blagosklonny, is an oncology professor at Roswell Park Cancer Institute in New York. He began his career with Roswell in 2009 and brought extensive experience and skill with him. His research includes cancer, cancer targeted therapies, aging, and anti-aging drugs. Through his research, he has developed a hypothesis regarding TOR signaling in aging as well as cancer. He has suggested using rapamycin, a cancer drug, as a possibility for extending lives. He is seen as a passionate advocate for further research into this use. Dr. Blagosklonny believes normal cells can be protected from damage through this therapy and that it can even cure cancer. Additionally, he has authored many articles on hyper function theory to aging and anti cancer approach called chemotherapeutic engineering and cell cyclotherapy. He was driven into this field by his desire to build a disease free world, and his deep love for humanity. Read more on Impact Journals.
Dr. Blagosklonny is an accomplished writer, and has written more than 300 articles, reviews, and chapters in books. He is the Editor in Chief of Aging and Cell Cycle. He currently or previously was the Associated Editor for Cancer Biology & Therapy, Cancer Research, Cell Death & Differentiation, Autophagy, International Journal of Cancer, American Journal of Pathology, and PLOS ONE.
Mikhail Blagosklonny earned his M.D. and PhD from First Pavlov State Medical University of St. Petersburg. His M.D. is in internal medicine and his PhD is in experimental medicine and cardiology. Previously, he served as an associate professor of medicine at New York Medical College in Valhalla, New York and as a senior scientist at Ordway Research Institute at Albany, New York.
Visit ResearchGate.Net to learn more about Mikhail’s latest work.